Vivoryon Therapeutics N.V.
VVY | AS
Overview
Corporate Details
- ISIN(s):
- NL00150002Q7
- LEI:
- 3912004AMB0KGZXZYJ15
- Country:
- Germany
- Address:
- Weinbergweg 22, 06120 Halle (Saale)
- Website:
- https://www.vivoryon.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Vivoryon Therapeutics N.V. is a clinical-stage precision medicine company focused on developing first-in-class, small molecule-based therapies for patients suffering from severe age-related diseases. The company leverages its in-depth expertise in post-translational modifications to develop medicines that modulate the activity and stability of proteins altered in disease settings. Its primary focus is on inhibiting glutaminyl cyclases (QPCT and QPCTL), enzymes implicated in the pathology of inflammatory, fibrotic, and neurodegenerative diseases, as well as cancer. Vivoryon's most advanced product candidate is varoglutamstat, an orally administered small molecule inhibitor of QPCT and QPCTL.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Vivoryon Therapeutics N.V..
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-21 14:00 |
Regulatory News Service
VeonGen Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT)…
|
English | 7.6 KB | |
| 2025-06-27 07:36 |
Report Publication Announcement
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences
|
English | 649.6 KB | |
| 2025-06-17 07:52 |
Earnings Release
Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress
|
English | 716.2 KB | |
| 2025-06-11 07:44 |
Report Publication Announcement
Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational …
|
English | 650.9 KB | |
| 2025-06-06 10:30 |
Regulatory News Service
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND …
|
English | 654.5 KB | |
| 2025-06-05 14:00 |
Regulatory News Service
ViGeneron Rebrands as VeonGen Therapeutics and Announces FDA Rare Pediatric Dis…
|
English | 8.8 KB | |
| 2025-05-27 07:44 |
Regulatory News Service
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S…
|
English | 686.4 KB | |
| 2025-04-29 07:02 |
Annual Report
Vivoryon Therapeutics N.V., Jaarlijkse financiële verslaggeving
|
English | 10.7 MB | |
| 2025-04-25 07:42 |
Capital/Financing Update
Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million
|
English | 656.2 KB | |
| 2025-02-11 18:12 |
Report Publication Announcement
Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on Febr…
|
English | 629.7 KB | |
| 2024-12-10 07:49 |
Earnings Release
Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on V…
|
English | 674.7 KB | |
| 2024-11-20 17:07 |
Earnings Release
Probiodrug announces encouraging results of the Phase 2a SAPHIR Study
|
English | 2.0 MB | |
| 2024-10-28 07:39 |
Earnings Release
Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutam…
|
English | 722.2 KB | |
| 2024-10-11 16:18 |
Regulatory News Service
Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the Ame…
|
English | 222.8 KB | |
| 2024-10-01 07:40 |
Regulatory News Service
Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Ev…
|
English | 210.7 KB |
Automate Your Workflow. Get a real-time feed of all Vivoryon Therapeutics N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Vivoryon Therapeutics N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-04-01 | E. Platzer | Executive member | Buy | 123,809 | 1,299,994.50 EUR |
| 2022-04-01 | U. Dauer | Executive member | Buy | 4,761 | 49,990.50 EUR |
| 2020-12-02 | D.J. von der Osten | Executive member | Buy | 20,000 | 112,400.00 EUR |
| 2020-11-30 | M. Schaeffer | Executive member | Other | 3,867 | N/A |
